DETROIT, Sept. 23 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) announced that on September 20, 2009, Georges Ugeux resigned as a director of the Company and from the audit, compensation and independent committees of the Board. Mr. Ugeux was the chairman of the independent committee.
In his resignation letter, Mr. Ugeux indicated that he had disagreements with the majority shareholder and senior management of the Company relating to corporate governance and the fiduciary role of independent directors. The Company believes that Mr. Ugeux's disagreements relate to the role of the independent directors going forward in managing the FDA actions previously disclosed by the Company. The current Board, including all the independent directors, believe that management of the FDA actions is and should remain the top priority and focus for the entire management team of the Company, with the entire Board providing the necessary oversight.
All of the members of the current Board, including the independent directors, believe that all shareholders' interests are aligned, and that the Company is moving in the right direction to enable it to resolve the FDA's concerns as expeditiously as possible. In this connection, the Company has engaged highly regarded (i) special FDA counsel to negotiate with the FDA on behalf of the Company and (ii) FDA consultants who are advising and will advise the Company with respect to compliance with FDA requirements. The Board is focused and resolute in its desire to resolve the FDA's concerns, and believes that it is acting in the best interests of all of the Company's shareholders, as resolution of such concerns will benefit all of the shareholders of the Company.
Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers.
Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limitation, the words "believe" or "expect" and similar expressions are intended to identify forward-looking statements. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties are contained in the Corporation's filings with the Securities and Exchange Commission, including Part I, Item 1A of our most recent Form 10-K, and include but are not limited to: information of a preliminary nature that may be subject to adjustment, potentially not obtaining or delay in obtaining FDA approval for new products, governmental restrictions on the sale of certain products, development by competitors of new or superior products or less expensive products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launches, dependence on few products generating majority of sales, product liability claims for which the Company may be inadequately insured, material litigation from product recalls, the purported class action lawsuits alleging federal securities laws violations, delays in returning the Company's products to market, including loss of market share, increased reserves against the FDA-seized inventory, and other risks identified in this report and from time to time in our periodic reports and registration statements. These forward-looking statements represent our judgment as of the date of this report. We disclaim, however, any intent or obligation to update our forward-looking statements.
Caraco Pharmaceutical Laboratories, Ltd.
CONTACT: Jitendra Doshi, +1-313-871-8400, or Thomas Versosky,
+1-313-556-4150, both of Caraco Pharmaceutical
Web Site: http://www.caraco.com/
